Reverse Seroconversion of Hepatitis B Virus after Hematopoietic Stem Cell Transplantation
| Autor: | Mineo Kurokawa, Masahito Kawazu, Hisamaru Hirai, Yoshinobu Kanda, Yasuhito Nannya, Masataka Takeshita, Shigeru Chiba, Katsunori Aoki, Toru Motokura, Shiho Tsujino, Yasushi Shiratori, Tetsuya Nakamoto, Seishi Ogawa, Yukiko Komeno, Miyuki Niino, Susumu Goyama |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Hepatitis B virus Cancer Research medicine.medical_treatment Hematopoietic stem cell transplantation medicine.disease_cause Transplantation Autologous Adrenal Cortex Hormones immune system diseases Humans Transplantation Homologous Medicine In patient Hepatitis B Surface Antigens business.industry Hematopoietic Stem Cell Transplantation Immunosuppression Hematology Middle Aged Hepatitis B Autologous bone Hepatitis B Core Antigens Virology Transplantation surgical procedures operative Oncology Immunology Reverse seroconversion Virus Activation business Complication |
| Zdroj: | Leukemia & Lymphoma. 43:2159-2163 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Hepatitis B virus (HBV) reactivation in patients previously positive for hepatitis B surface antibody (HBsAb), so-called reverse seroconversion, has been considered to be a rare complication after hematopoietic stem cell transplantation (HSCT). We experienced two patients who developed reverse seroconversion among nine who were HBsAb positive and Hepatitis B core antibody (HBcAb) positive before HSCT; one after autologous bone marrow transplantation (BMT) and another after allogeneic peripheral blood stem cell transplantation (PBSCT). We reviewed the literature and considered that reverse seroconversion of HBV after HSCT is not uncommon among HBsAb positive recipients. The use of corticosteroids, the lack of HBsAb in donor, and a decrease in serum HBsAb and HBcAb levels may predict reverse seroconversion after HSCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|